Erlotinib

Erlotinib is an EGFR inhibitor (Ki = 2.7 nM). It is greater than 1,000-fold selective for EGFR over Src and Abl at 0.1 µM. Erlotinib induces caspase-3 and -7 activity in NCI H358 non-small cell lung cancer (NSCLC) cells when used at a concentration of 1 µM. Erlotinib (25 mg/kg) reduces EGF-induced EGFR autophosphorylation in an HN-5 head and neck cancer mouse xenograft model. Formulations containing erlotinib have been used in the treatment of various cancers.Formal Name: N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine. CAS Number: 183321-74-6. Synonyms: NSC 718781. Molecular Formula: C22H23N3O4. Formula Weight: 393.4. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 50 mg/ml, DMF:PBS (pH 7.2) (1:9): 0.1 mg/ml, DMSO: 25 mg/ml, Ethanol: 0.25 mg/ml. lambdamax: 247, 333 nm. SMILES: C#CC1=CC(NC2=NC=NC3=CC(OCCOC)=C(OCCOC)C=C32)=CC=C1. InChi Code: InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25). InChi Key: AAKJLRGGTJKAMG-UHFFFAOYSA-N.